CHOP

Santhera Pharmaceuticals is conducting a phase 3 trial of the antioxidant idebenone in Duchenne muscular dystrophy

posted on December 15, 2010 - 11:22am
A large-scale, phase 3 trial of idebenone (Catena) in Duchenne muscular dystrophy (DMD) is now open at one U.S. site and several sites in Europe, under the auspices of Santhera Pharmaceuticals.

New content is being added every day. Please check back again.